The Critical Limb Ischemia drugs in development market research report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Critical Limb Ischemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Critical Limb Ischemia by 30 companies/universities/institutes. The top development phase for Critical Limb Ischemia is preclinical with 14 drugs in that stage. The Critical Limb Ischemia pipeline has 32 drugs in development by companies and two by universities/ institutes. Some of the companies in the Critical Limb Ischemia pipeline products market are: Reven, Ambulero and Elphis Cell Therapeutics.
The key targets in the Critical Limb Ischemia pipeline products market include E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE), Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), and Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2).
The key mechanisms of action in the Critical Limb Ischemia pipeline product include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Activator with two drugs in Phase III. The Critical Limb Ischemia pipeline products include ten routes of administration with the top ROA being Intramuscular and eight key molecule types in the Critical Limb Ischemia pipeline products market including Cell Therapy, and Gene Therapy.
Critical Limb Ischemia overview
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet, and hands. Symptoms include pain or numbness in feet or toes, sores, and skin infections that do not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life, and increasing survival.
For a complete picture of Critical Limb Ischemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
